1
• Surgery is the only accepted treatment for cataracts 2 • Cystoid macular edema (CME) is the most frequent postoperative complication associated with cataract surgery which leads to vision loss 3 • Loss of visual acuity in CME patients causes substantial functional impairment and decreased quality of life 3 • Patients with diabetes have a higher risk of pain and CME following surgery 4 • Topical corticosteroids and NSAIDs are used for the treatment of pain and inflammation and for the reduction in risk of CME associated with cataract surgery 5 • Nepafenac 3 mg/ml has recently been approved by the EMA for the reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients 6 • Nepafenac 1 mg/ml (thrice a day dosage) and 3 mg/ml (once a day dosage) are the only NSAIDs approved by the EMA for this indication 6 
Objective
• To estimate the cost-effectiveness of nepafenac 3 mg/ml vs. vehicle (steroid therapy alone) from UK NHS perspective, using recently available clinical data
Methods

Cost-effectiveness model
• Excel-based decision tree model was used to compare the costeffectiveness of nepafenac 3 mg/ml add-on to standard ocular steroid therapy versus steroid therapy alone (See figure 1) • Time horizon in the model was 1 year • The incidence of CME by treatment arm was derived from a pooled analysis of the two confirmatory trials for nepafenac 3 mg/ml 7, 8 • Cost estimates were specific to the UK only, including intervention costs and costs related to CME, with the latter including drug costs, administration costs and monitoring costs
• Costs associated with CME were assumed to be incurred only by patients with a clinical CME diagnosis
• Unit costs for various resource utilization were obtained from regional unit cost price lists and drug prices from MIMS online and Medicines.org.UK etc 9, 10 • CME related resource use for drug administration and monitoring was 
Model inputs:
• The inputs and model settings are summarized in Table 1 . Pooled results from C-12-067 and C-12-071 taken for CME incidence following cataract surgery for nepafenac and vehicle patients
• Intervention costs are considered as price per bottle and the number of bottles used. Nepafenac 3 mg/ml 3 ml bottle cost is assumed to be the same as nepafenac 1 mg/ml 5 ml bottle for the analysis since no published price for nepafenac 3 mg/ml is available. Nepafenac 3 mg/ml 2 bottles are assumed to be used for 60 days
• Steroid therapy was used for only 4 weeks in both arms, but the cost of steroid is not considered for the current analysis since it is assumed to be same in both arms
• Drug costs, drug administration, monitoring visits are applied to patients who developed CME. Though there is a provision to include societal costs, these were kept zero for the current analysis 
Results
Base case:
• Table 2 shows the base-case results. Nepafenac 3 mg/ml led to an increase in 0.003 QALYs and a cost-saving of £153 versus steroid therapy alone for reducing the risk of CME associated with cataract surgery in diabetic patients • Nepafenac was found to be dominant, i.e. less costly and more effective than standard of care (treatment with steroids alone)
• This result was primarily driven by the effectiveness and low price of nepafenac and the comparably substantial cost offsets associated with avoided CMEs Sensitivity analysis
• Figure 3 shows Tornado diagram. Decrease in logMAR for
Nepafenac and Vehicle were the key parameters for driving the cost-effectiveness 
Limitations
• The nepafenac clinical trials estimated visual acuity only in the operated eye while most patient reported outcome studies relate QoL to the visual acuity in the betterseeing eye 11 • The nepafenac clinical trial estimated the effect on CME for 90 days while the approved EMA indication is for 60 days. A payer may thus argue that the model overestimates the effectiveness they are asked to pay for
Conclusion
• Nepafenac 3 mg/ml is an economically dominant treatment (is more effective and less costly) compared to steroid therapy alone in the UK NHS setting
